Athira Pharma to Participate in Upcoming May Conferences

Athira Pharma to Participate in Upcoming May Conferences

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May.

Sidoti May 2024 Virtual Investor Conference
Format: Company Presentation
Date and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET
Location: Virtual

The Citizens JMP Life Sciences Conference
Format: Fireside Chat
Date and Time: Monday, May 13, 2024, from 1:30 p.m. - 1:55 p.m. ET
Location: New York Hilton Midtown

Live webcasts of the panel and presentations can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor . An archived replay of the webcasts will be available for at least 30 days following the event.

About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton, which is being evaluated for the potential treatment of mild-to-moderate Alzheimer's disease in the Phase 2/3 LIFT-AD trial that is expected to report topline data in the second half of 2024. For more information, visit www.athira.com . You can also follow Athira on Facebook , LinkedIn and @athirapharma on X , (formerly known as Twitter ) , and Instagram .

Investor Contacts:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219

Anne Marie Fields
Stern Investor Relations
annemarie.fields@sternir.com
332-213-1956

Media Contact:
Janine Bogris
Inizio Evoke Comms
Janine.bogris@inizioevoke.com
201-245-6838


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ATHA
The Conversation (0)
Greenridge Exploration Enters into Binding Arrangement Agreement to Acquire ALX Resources Corp.

Greenridge Exploration Enters into Binding Arrangement Agreement to Acquire ALX Resources Corp.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Greenridge Exploration Inc. (CSE: GXP) (FSE: HW3)  ("Greenridge" or the "Company") and alx resources corp. ("ALX" and collectively with Greenridge, the "Parties") (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) are pleased to announce the signing of a binding arrangement agreement (the "Arrangement Agreement") dated October 11, 2024 pursuant to which Greenridge will acquire all of the outstanding and issued common shares of ALX (the "Transaction"). The Transaction is an arm's length transaction that will create a leading Canadian uranium exploration company with interests in sixteen (16) uranium exploration projects that total approximately 220,000 hectares across renowned Canadian uranium districts including the Athabasca Basin, Thelon Basin and Elliot Lake. The combined entity will have interests in an additional thirteen (13) lithium, nickel, gold and copper properties across Canada. The Arrangement Agreement follows the non-binding letter of intent announced by the Company on September 5, 2024.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
SAGA Metals Completes IPO with Focus on Uranium Exploration and Rio Tinto Partnership

SAGA Metals Completes IPO with Focus on Uranium Exploration and Rio Tinto Partnership

Saga Metals Corp. (" TSXV: SAGA ") (" SAGA " or the " Company "), a North American exploration company focused on critical mineral discovery in Canada, is pleased to announce the successful closing of its initial public offering (IPO) and provide updates on its major projects. SAGA shares began trading on the TSX Venture Exchange (TSXV) under the symbol "SAGA" on September 24, 2024.

A Strategic Focus on Critical Minerals in North America

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Baselode Defines the Significance of Massive Clay Alteration System Identified on Hook Uranium Project

Baselode Defines the Significance of Massive Clay Alteration System Identified on Hook Uranium Project

  • Five drill holes outlined an open massive hydrothermal clay alteration system measuring at least 200 m x 100 m, resembling alteration found in Athabasca high-grade uranium deposits
  • Radioactivity within the clay alteration system increases with depth and remains open
  • Drill hole HK24-010 intersected 13.4 metres of continuous radioactivity within a 200 m wide alteration system
  • New defined target areas are within 6 km of near-surface ACKIO uranium prospect

Baselode Energy Corp. (TSXV: FIND) (OTCQB: BSENF) ("Baselode" or the "Company") is pleased to provide results and findings from the exploration and discovery portion of the drill program on Hook project ("Hook") in the Athabasca Basin area of northern Saskatchewan.

"These results represent an important discovery on our Hook project. While we've already made a discovery at Hook with ACKIO, this is only a small part of the broader Hook land package. The potential on the property is substantial as Hook is an extensive project, and our discovery at ACKIO, combined with our neighbour Atha Energy's discovery in their Gemini Mineralized Zone, highlights that the region has all the geological features needed to host significant uranium deposits. More importantly, we can clearly demonstrate that this area is fertile with uranium mineralization. Large-scale alteration systems are key indicators when it comes to uranium, which tends to occur in smaller deposits relative to other minerals. We're pleased to have uncovered such a large system, exhibiting all the hallmark features needed for a new high-grade Athabasca uranium discovery," commented James Sykes, CEO, President, and Director of Baselode.

Watch this video for a detailed analysis of the two follow-up target areas and a comparison of Hook alteration systems to seven Athabasca high-grade uranium deposits that have combined over 700 million pounds of uranium.

The first alteration system the Company highlights is in the HK24-016 area, measuring more than 250 metres wide by 400 metres deep, with a core of massive clay and bleached alteration styles that measure 100 metres wide by at least 200 metres deep. These core alteration styles are important as they are the same style associated with at least three basement-hosted Athabasca high-grade uranium deposits.

The second alteration system identified in the HK24-010 area is significant due to its similarly large scale, intersecting 13 meters of continuous anomalous radioactivity within pegmatite along the margin of the fluid pathway. While assays are pending, the Company is well-funded and eager to proceed with follow-up drill plans for these high-priority exploration targets.

Hook Exploration Drill Hole Highlights

HK24-016 area

Drill holes HK24-016, HK24-017, and HK24-021 to HK24-023 were collared 5.5 kilometres southwest of ACKIO (Figure 2, Figure 3). HK24-016 intersected 140 metres of massive hydrothermal clay and bleaching alteration (the "clay alteration") within a broader 370 m thick alteration corridor (Figure 4). The drill hole intersected anomalous radioactivity associated with fracture-controlled remobilized hematite alteration within the clay alteration (Figure 5).

Both HK24-017 and HK24-021 targeted the clay alteration up-dip and down-dip, with each intersecting 30 and 145 metres of clay alteration, respectively. HK24-022 was collared 100 metres southeast of HK24-016 and intersected 60 metres of clay alteration, and HK24-023 was collared 50 metres northeast and intersected 110 metres of clay alteration. Initial observations suggests follow-up drilling is required beneath HK24-021 and to the north of HK24-023.

The clay alteration encountered within these Hook drill holes (Figure 6) share numerous similarities to massive hydrothermal clay alteration systems observed in Athabasca basement-hosted, high-grade uranium systems, such as Cameco's Millennium and Eagle Point deposits, Uranium Energy Corp's Roughrider deposits, and Denison Mines' Gryphon deposit.

The upper outer halo of the clay alteration is further identified with unique limonite liesegang banding and fracture-controlled alteration, including a distinct quartz stockwork. These are also similar outer halo alteration styles that have been observed within large-scale Athabasca uranium deposits.

HK24-010 area

Drill holes HK24-009 and HK24-010 were collared 6 kilometres northeast of ACKIO (see Figure 2, Figure 7). Details of these drill holes were initially released on July 17, 2024. HK24-010 has returned the best radioactive intersection outside of Baselode's near-surface ACKIO uranium prospect with 13.2 metres of continuous anomalous radioactivity starting at 186 metres beneath the surface hosted within a pegmatite along the western margin of a 200 m-wide, structurally-controlled, hematite and bleached alteration system. The area remains open in all directions.

Drill hole samples have been sent to Saskatchewan Research Council for uranium and multi-element analysis. Results will be released after being received and reviewed by the Company.

NOTES:

  1. cps* = "counts-per-second", as measured with a handheld RS-125 Gamma-Ray Spectrometer/Scintillometer ("RS-125"). The reader is cautioned that Baselode uses scintillometer readings as a preliminary indication for the presence of radioactive materials (uranium, thorium and/or potassium), and that scintillometer results may not be used directly to quantify or qualify uranium concentrations of the rock samples measured.
  2. The Company defines groupings of RS-125 as i) background radioactivity (50 to 200 cps), ii) above-background radioactivity (200 to 300 cps), and iii) anomalous radioactivity (300 to 1,000 cps).
  3. "Radioactivity (>300 cps)" in Table 1 is defined as drill core length with no greater than 2.0 m of consecutive drill hole length measuring less than 300 cps.
  4. All reported drill hole depths and lengths do not represent true thicknesses.

About Baselode Energy Corp.

Baselode controls 100% of approximately 238,930 hectares for exploration in the Athabasca Basin area of northern Saskatchewan, Canada. The land package is free of any option agreements or underlying royalties.

The Company discovered the ACKIO near-surface, uranium prospect in September 2021. ACKIO measures greater than 375 m along strike, greater than 150 m wide, comprised of at least 9 separate uranium Pods, with mineralization starting as shallow as 28 m and 32 m beneath the surface in Pods 1 and 7, respectively, and down to approximately 300 m depth beneath the surface with the bulk of mineralization occurring in the upper 120 m. ACKIO remains open at depth, and to the north, south and east.

Baselode's Athabasca 2.0 exploration thesis focuses on discovering near-surface, basement-hosted, high-grade uranium orebodies outside the Athabasca Basin. The exploration thesis is further complemented by the Company's preferred use of innovative and well-understood geophysical methods to map deep structural controls to identify shallow targets for diamond drilling.

QP Statement

The technical information contained in this news release has been reviewed and approved by Cameron MacKay, P.Geo., Vice-President, Exploration & Development for Baselode Energy Corp., who is considered to be a Qualified Person as defined in "National Instrument 43-101, Standards of Disclosure for Mineral Projects."

For further information, please contact:

James Sykes, CEO, President and Director
Baselode Energy Corp.
jsykes@oregroup.ca
306-221-8717
www.baselode.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the TSX Venture Exchange policies) accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. Baselode Energy Corp. assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to Baselode Energy Corp. Additional information identifying risks and uncertainties is contained in the Company's filings with Canadian securities regulators, which filings are available under Baselode Energy Corp. profile at www.sedarplus.ca.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws, unless an exemption from such registration is available.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6412/224182_480ec88df46cda96_001.jpg

FIGURE 1 - Baselode projects location map. ACKIO uranium prospect identified with yellow circle.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6412/224182_480ec88df46cda96_001full.jpg

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6412/224182_480ec88df46cda96_002.jpg

FIGURE 2 - Drill holes (HK24-009 to HK24-023) location map

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6412/224182_480ec88df46cda96_002full.jpg

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6412/224182_480ec88df46cda96_005.jpg

FIGURE 3 - HK24-016 target area drill holes (HK24-016, HK24-017, and HK24-021 to HK24-023) location map

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6412/224182_480ec88df46cda96_005full.jpg

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6412/224182_480ec88df46cda96_006.jpg

FIGURE 4 - Cross-section interpretation of large hydrothermal fluid system with core massive clay and bleaching alteration (blue)

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6412/224182_480ec88df46cda96_006full.jpg

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6412/224182_480ec88df46cda96_007.jpg

FIGURE 5 - Fracture-controlled, hydrothermal remobilized anomalous radioactivity, HK24-016

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6412/224182_480ec88df46cda96_007full.jpg

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6412/224182_480ec88df46cda96_008.jpg

FIGURE 6 - Massive clay and bleaching alteration system, HK24-021. NOTE: clay has been gouged with carbon scribe to demonstrate drill core softness

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6412/224182_480ec88df46cda96_008full.jpg

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6412/224182_480ec88df46cda96_020.jpg

FIGURE 7 - HK24-010 target area drill holes (HK24-009 and HK24-010) location map

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6412/224182_480ec88df46cda96_020full.jpg

MOVIE 1 - Clay alteration and bleaching identified within drill hole HK24-021

Keep reading...Show less
Skyharbour Appoints Athabasca Basin Veteran, Serdar Donmez, as Vice President of Exploration

Skyharbour Appoints Athabasca Basin Veteran, Serdar Donmez, as Vice President of Exploration

Skyharbour Resources Ltd.'s (TSX-V: SYH ) (OTCQX: SYHBF ) (Frankfurt: SC1P ) (the "Company") is pleased to announce the appointment of Serdar Donmez, a recognized geoscientist with decades of experience in uranium exploration and development, as Vice President of Exploration. Mr. Donmez will be working with the rest of Skyharbour's geological team based in Saskatoon.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Greenridge Exploration Announces Letter of Intent to Acquire ALX Resources Corp.

Greenridge Exploration Announces Letter of Intent to Acquire ALX Resources Corp.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Greenridge Exploration Inc. (CSE: GXP) (FSE: HW3) ("Greenridge" or the "Company") and alx resources corp. ("ALX") (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) are pleased to announce the signing of a non-binding letter of intent ("LOI") dated September 4, 2024 pursuant to which Greenridge will acquire all of the outstanding and issued common shares of ALX (the "Proposed Transaction"). The Proposed Transaction is an arm's length transaction that will create a leading Canadian uranium exploration company with interests in 15 uranium exploration projects that total approximately 276,000 hectares across renowned Canadian uranium districts including the Athabasca Basin, Thelon Basin and Elliot Lake. The combined entity will have interests in an additional 13 lithium, nickel, gold and copper properties across Canada.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Amplia Therapeutics

Interim Data from Accent Pancreatic Cancer Trial Supports Continuation of Trial

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to report the interim data analysis from the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial). The trial is investigating the combination of the Company’s best-in-class FAK inhibitor narmafotinib with the standard-of-care chemotherapy regimen of gemcitabine and Abraxane®. Data cut-off for the interim analysis is 27 September 2024.

Keep reading...Show less
  InhaleRX

InhaleRx Secures $38,500,000 Funding to Fully Fund Clinical Development Plans

InhaleRx Ltd (ASX: IRX) (‘InhaleRx’ ‘IRX’ or ‘the Company’), an Australian healthcare company developing unique drug-device products to address unmet medical needs in pain management and mental health sectors, is pleased to announce that it has entered into a significant funding agreement with Clendon Biotech Capital Pty Ltd (‘Clendon Biotech Capital’). This strategic partnership will provide the funding to cover all direct costs associated with the Phase 1 & 2 clinical development of the Company's key projects - IRX-211 and IRX-616a.

Keep reading...Show less
  TrivarX

Positive results from Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) Study

TrivarX Limited (‘the Company’) (ASX: TRI) is pleased to announce positive top-line results from the Company’s recently completed Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) study utilising its proprietary AI-backed algorithm, MEB-001. MEB-001 uses EEG and ECG signals recorded during sleep to identify current Major Depressive Episode (cMDE).

Keep reading...Show less
Tryptamine Therapeutics Limited

Positive Phase 2a Fibromyalgia Results Deliver Pain Reduction in 100% of Patients, Strengthening IP Position and Clinical Trial Strategy

Tryptamine Therapeutics Limited (‘Tryp’ or the ‘Company’) (ASX: TYP), a clinical-stage biotechnology company is pleased to advise it has received highly encouraging, positive results from its recently completed Phase 2a clinical trial conducted in collaboration with the University of Michigan (‘UOM’) (refer ASX announcement: 10 July 2024). The results are both significant and clinically meaningful, and were presented by UOM researchers at the International Association for the Study of Pain (‘IASP’) 2024 World Congress in the Netherlands on 9 August 2024.

Keep reading...Show less
  LTR Pharma Limited

LTP Secures Global Co-Development Agreement with Aptar Pharma

LTR Pharma Limited (ASX:LTR) (“LTR Pharma”, “the Company”) is pleased to announce that it has entered into a Co-Development Agreement (“the Agreement”) for SPONTAN for global markets.

Keep reading...Show less
CHIMERIC THERAPEUTICS LIMITED

First Patient Enrolled in CHM CDH17 Phase 1/2 Clinical Trial

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce that the first participant has been enrolled in the Phase 1/2 multi-centre clinical trial for CHM CDH17 cell therapy.

Keep reading...Show less

Latest Press Releases

Related News

×